• Cabazitaxel (XRP6258): Technical Use in Resistant Tumor Mode

  2026-07-28

  Cabazitaxel (XRP6258) offers a practical antiproliferative agent for research on taxane-resistant and P-glycoprotein-expressing cancer cell lines. It should be applied in DMSO or ethanol-based assays, not in water-based or long-term storage protocols. Researchers benefit most by following strict solvent and handling guidelines.

• Efficient Synthesis of Deuterium-Labeled Degarelix Acetate:

  2026-07-27

  This study presents a novel and efficient approach for synthesizing deuterium-labeled degarelix acetate, a third-generation GnRH receptor antagonist, utilizing D2O/D3PO4 as the deuterium source. The innovation streamlines internal standard preparation for pharmacokinetic studies, supporting advanced metabolism and biomarker research in androgen-related diseases.

• Triiodothyronine in Beige Adipocyte Thermogenesis Research

  2026-07-27

  Explore how Triiodothyronine (T3) enables advanced investigation of beige adipocyte differentiation, thermogenesis, and metabolic regulation. This article uniquely bridges thyroid hormone signaling to the latest mechanistic insights, offering practical guidance for metabolic and cellular assay design.

• Baicalin Methyl Ester Restores LPS-Damaged Intestinal Barrie

  2026-07-26

  This study demonstrates that baicalin methyl ester, an esterified derivative of baicalin, prevents LPS-induced intestinal barrier damage in both in vivo and in vitro models by modulating the P65/TNF-α/MLCK/ZO-1 signaling pathway. The findings provide robust mechanistic and translational evidence supporting its use as a targeted anti-inflammatory agent in intestinal barrier research.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-07-25

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in peptide synthesis, bioconjugation, and nucleotide coupling workflows. It provides a practical solution for chemists requiring robust, in vitro coupling chemistry in aqueous or mixed solvent systems. This reagent is not suitable for in vivo or clinical applications.

• MLN8237 (Alisertib): Mechanistic Insights and Assay Strategy

  2026-07-24

  Explore the mechanistic depth and assay innovation of MLN8237 (Alisertib), a selective Aurora A kinase inhibitor. This article bridges molecular findings with practical assay design, offering unique guidance for cancer biology research.

• ASB3 E3 Ligase Regulates MAVS and Antiviral Innate Immunity

  2026-07-24

  The referenced study uncovers ASB3 as a negative regulator of antiviral innate immunity by targeting the MAVS adaptor protein for ubiquitin-proteasomal degradation. This mechanistic insight advances our understanding of host-virus interactions and opens new avenues for dissecting innate immune signaling using advanced fluorescence-based detection platforms.

• ESCO2 in Pan-Cancer: Prognostic Insights and Cell Cycle Impl

  2026-07-23

  A recent pan-cancer analysis clarifies the oncogenic role of ESCO2, highlighting its overexpression in most tumor types and its influence on prognosis and cell proliferation. The findings suggest ESCO2 as a promising biomarker and therapeutic target, with implications for precise cell cycle analysis in diverse cancer research contexts.

• Deferasirox Modulates Myeloid Differentiation via Mitochondr

  2026-07-23

  This study reveals that Deferasirox, an oral iron chelator, disrupts myeloid differentiation by modulating mitochondrial ROS and NF-κB pathway activity in both human and murine models. The findings clarify stage-specific effects of Deferasirox on hematopoietic cells, with implications for iron overload treatment research and beta-thalassemia management.

• ZK53: Unveiling Selective ClpP Activation for Mitochondrial

  2026-07-22

  Discover how ZK53, a human mitochondrial serine protease ClpP activator, uniquely enables targeted disruption of mitochondrial function and cell cycle arrest in cancer models. This article delivers an advanced, evidence-based perspective on ZK53’s mechanistic selectivity and translational impact.

• Synthetic Viability with ERCC1 Deficiency in Lung Cancer ICL

  2026-07-22

  Heyza et al. reveal how p53 status modulates lung cancer cell survival following ERCC1 loss and interstrand crosslink (ICL) damage, challenging the predictive power of ERCC1 as a clinical platinum response biomarker. Their CRISPR-based study clarifies the interplay between DNA repair pathways, apoptosis, and chemoresistance, informing design of future platinum-based regimens and mechanistic studies.

• NS1-Driven DNMT1 Degradation Shapes Bocavirus Replication an

  2026-07-21

  This study uncovers how the NS1 protein of human bocavirus 1 (HBoV1) mediates DNMT1 degradation, reshaping viral DNA methylation and altering both the replication and RNA processing of the virus. The findings highlight a pivotal role for host epigenetic regulation in the HBoV lifecycle and point to DNMT1 as a promising antiviral target.

• Substrate Stiffness Drives Dentinogenesis via LAMB1–FAK–MEK1

  2026-07-21

  This study demonstrates that substrate stiffness directly regulates odontoblast-like cell differentiation and dentin formation through a LAMB1–FAK–MEK1/2 signaling pathway. The findings reveal how mechanical cues at cell–material interfaces can influence dental tissue engineering strategies by engaging focal adhesion kinase (FAK)-centered mechanotransduction.

• Selonsertib (GS-4997): ASK1 Inhibition in Fibrosis & NAFLD M

  2026-07-20

  Selonsertib (GS-4997) is a highly selective ASK1 inhibitor that blocks oxidative stress pathways central to fibrosis and metabolic liver disease research. Preclinical benchmarks demonstrate its utility in dissecting inflammation and autophagy crosstalk in NAFLD and diabetic kidney disease models. The compound’s specificity for stressed cells makes it a valuable tool for translational research.

• Strategic Use of WP1066 for Translational JAK2/STAT3 Modulat

  2026-07-20

  WP1066, a potent cell-permeable JAK2/STAT3 inhibitor from APExBIO, is reshaping translational research by enabling targeted pathway modulation across oncology and regenerative medicine. This thought-leadership article explores the mechanistic rationale, experimental workflows, and strategic considerations for deploying WP1066 in cancer and bone defect models, with a critical look at cross-domain opportunities and limitations.

453 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page